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Abstract 
 
                    A retrospective molecular analysis for Human papillomavirus types 
16 and18 was done on 40 formalin- fixed paraffin- embedded cervical 
biopsies, previously collected from women in the Central Sudan and 
histopathologically diagnosed as cervical cancer. According to the age, the 
women were divided into two groups ≤ 44 were 30% and ≥ 45 were 70%. 
DNA was extracted using DNA extraction kit. Type specific polymerase 
chain reaction (PCR) kit that contained primers for HPV16 together with 
primers for HPV18  was used to detect Human papillomavirus types 16 and 
18 and to determine the prevalence of each type and also to determine the 
association of these HPVs DNA to various grades of cervical carcinoma.   
  PCR results showed that HPV16 and 18 were detected in 14 (35%) 
of the  study specimens. HPV16 was detected in 57.1% (8/14). and HPV 18 
was detected in 28.6% (4/14). Mixed infections were detected in 14.3% 
(2/14) 0f positive samples, Accordingly, HPV 16 is the most common HPV 
type associated with cervical carcinoma in Central Sudan. The HPVs were 
detected in 10 individuals whose ages were ≥ 45 and in 4 individuals whose 
ages ≤ 44. Therefore, cervical cancer  is more common in woman older than 
45 years, suggesting infection at  a younger age and slow progressing to 
cancer.   
An interesting finding in this study was the relatively higher rate of 
HPV infection in the early stage of cancer. This finding reveals the 
importance of the use of HPV detection as screening tool for early detection 
of cervical cancer.   
It is recommended that a wide population-based epidemiological 
study be conducted to define the exact picture of this disease and to define 
types of HPV that are found in other parts of the Sudan. The use of 
suitable vaccine targeting these types will have substantial impact on 
cervical cancer control in the Sudan.   
 اﻟﺨـﻼﺻـﺔ 
 ﻤﻥ ﻋﻴﻨﺎﺕ ﺍﻟﻨﺴﺠﺔ ﺍﻟﻤﻐﻤﻭﺭﺓ ﻓﻲ ﺍﻟﺒﺭﺍﻓﻴﻥ 04ﺃﺠﺭﻴﺕ ﺩﺭﺍﺴﺔ ﺇﺴﺘﻌﺎﺩﻴﺔ ﺠﺯﺌﻴﺔ ﻋﻠﻰ 
ﻭ ﺍﻟﻤﺜﺒﺘﺔ ﺒﺎﻟﻔﻭﺭﻤﺎﻟﻴﻥ ﻭ ﺍﻟﺘﻲ ﺴﺎﺒﻘﺎ ﺘﻡ ﺍﺨﺫﻫﺎ ﻤﻥ ﻨﺴﺎﺀ ﻓﻲ ﻭﺴﻁ ﺍﻟﺴﻭﺩﺍﻥ ﻭ ﺘﻡ ﺘﺸﺨﻴـﺼﻬﺎ 
ﻨﺴﻴﺠﻴﺎ ﻋﻠﻰ ﺍﻨﻬﺎ ﺴﺭﻁﺎﻥ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﻭ ﻗﺴﻤﺕ ﺍﻟﻌﻴﻨﺎﺕ ﺍﻋﺘﻤﺎﺩﺍ ﻋﻠﻰ ﺩﺭﺠﺔ ﺘﻤﺎﻴﺯ ﺍﻟﺨﻼﻴـﺎ 
ﻜـﺫﻟﻙ ﺘـﻡ ﺘﻘـﺴﻴﻡ .ﻤﺘﻭﺴﻁﺔ ﻭ ﺸﺩﻴﺩﺓ ﺘﻤﺎﻴﺯ ﺍﻟﺨﻼﻴﺎ ﺍﻟﺴﺭﻁﺎﻨﻴﺔ ،ﻴﻔﺔ ﺍﻟﺴﺭﻁﺎﻨﻴﺔ ﺍﻟﻰ ﻀﻌ 
ﺘﻡ ﺍﺴـﺘﺨﻼﺹ .  ﺴﻨﺔ 54 ≤  ﺴﻨﺔ  ﻭ 44 ≥ ﺍﻟﻤﺭﻴﻀﺎﺕ ﻋﻠﻰ ﺍﺴﺎﺱ ﺍﻟﻌﻤﺭ ﺍﻟﻰ ﻤﺠﻤﻭﻋﺘﻴﻥ
ﺜﻡ ﺒﻌﺩ ﺫﻟﻙ ﺘﻡ ﺍﻜﺜﺎﺭ ﺍﻟﺤﻤـﺽ ( tiK AND artxE)ﺍﻟﺤﻤﺽ ﺍﻟﻨﻭﻭﻱ ﺍﻟﺩﻴﻜﺴﻲ ﺒﺎﺴﺘﺨﺩﺍﻡ 
ﻭﺍﻟﺫﻱ ﻴﻀﻡ ﺒﺎﺩﺌـﺎﺕ ( RCP)ﺍﻟﻨﻭﻭﻱ ﺍﻟﻤﺴﺘﺨﻠﺹ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﺘﻔﺎﻋل ﺍﻻﻨﺯﻴﻤﻲ ﺍﻟﻤﺘﺴﻠﺴل 
 ﻭﺍﻟﺘﻲ ﻴﻬﺩﻑ ﺍﻟﻜﺸﻑ ﻋﻨﻬﺎ ﻓـﻲ ﻫـﺫﻩ ﺍﻟﺩﺭﺍﺴـﺔ 81ﻭ61ﻟﻜل ﻤﻥ ﻨﻤﻁﻲ ﻓﻴﺭﻭﺱ ﺍﻟﺒﺎﺒﻠﻭﻤﺎ 
ﻭﻟﺘﺤﺩﻴﺩ ﻨﺴﺒﺔ ﻜل ﻨﻤﻁ ﻭﺭﺍﺜﻲ ﻜﺫﻟﻙ ﻟﺘﺤﺩﻴﺩ ﻋﻼﻗﺔ ﻜل ﻨﻤﻁ ﻭﺭﺍﺜﻲ ﺒﻤﺩﻯ ﺘﻤـﺎﻴﺯ ﺍﻟﺨﻼﻴـﺎ 
     .ﺍﻟﺴﺭﻁﺎﻨﻴﺔ
ﻭ ﺍﻟﺫﻱ ﻜﺸﻑ ﻋﻥ ﻭﺠﻭﺩ ﺍﻟﺤﻤﺽ  (RCP)ﺘﻡ ﺇﺠﺭﺍﺀ ﺍﻟﺘﻔﺎﻋل ﺍﻻﻨﺯﻴﻤﻲ ﺍﻟﻤﺘﺴﻠﺴل 
 ﻭﻭﺠـﺩ  ،(04/41 % )53  ﺒﻨـﺴﺒﺔ 81 ﻭ61ﻴـﺭﻭﺱ ﺍﻟﺒﺎﺒﻠﻭﻤـﺎ ﻟﻠﻨﻤﻁـﻴﻥ ﺍﻟﻨـﻭﻭﻱ ﻟﻔ 
ﻜﻤـﺎ (. 41/6 % )6.34 ﻓﻭﺠﺩ ﺒﻨﺴﺒﺔ 81VPH ، ﺃﻤﺎ )41/8(% 1.75ﺒﻨﺴﺒﺔ 61VPH
 ﻫـﻭﺍﻜﺜﺭ 61ﻭﻤﻥ ﻫﻨﺎ ﻓﺎﻥ ﺍﻟﻨﻤﻁ ﺍﻟﻭﺭﺍﺜﻲ  )41/2( % 3.41 ﺒﻨﺴﺒﺔ 81+61VPHﻭﺠﺩ 
  .ﺩﺍﻥﺍﻻﻨﻤﺎﻁ ﺍﻟﻭﺭﺍﺜﻴﺔ  ﺸﻴﻭﻋﺎ ﻭ ﺍﻟﺘﻲ ﻟﻬﺎ ﻋﻼﻗﺔ ﺒﺴﺭﻁﺎﻥ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﻓﻲ ﺍﻟﺴﻭ
 ﺴﻨﺔ 54ﻜﺫﻟﻙ ﻭﺠﺩ ﺍﻥ ﻓﻴﺭﻭﺱ ﺍﻟﺒﺎﺒﻠﻭﻤﺎ ﻴﻜﺜﺭ ﻓﻲ ﺍﻟﻨﺴﺎﺀ ﺍﻟﻼﺌﻲ ﺍﻋﻤﺎﺭﻫﻥ ﺍﻜﺜﺭ ﻤﻥ 
  . ﺴﻨﺔ54ﺒﻴﻨﻤﺎ ﻴﻘل ﻓﻲ ﺍﻟﻼﺘﻲ ﺃﻋﻤﺎﺭﻫﻥ ﺩﻭﻥ ﺍل
 ﻴﺯﻴﺩ )81VPH dna 61VPH(ﻭﻤﻥ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻟﻤﻼﺤﻅﺔ ﻭﺠﺩ ﺃﻥ ﻓﻴﺭﻭﺱ ﺍﻟﺒﺎﺒﻠﻭﻤﺎ 
ﻫﻤﻴﺔ ﺍﺴﺘﺨﺩﺍﻡ ﻤﻌﺩل ﺘﻭﺍﺠﺩﻫﻤﺎ ﻓﻲ ﺍﻟﻤﺭﺍﺤل ﺍﻷﻭﻟﻲ ﻟﻺﺼﺎﺒﺔ ﺒﺎﻟﺴﺭﻁﺎﻥ، ﻭﻫﺫﻩ ﺍﻟﻨﺘﻴﺠﺔ ﺘﺄﻜﺩ ﺃ 
  . ﺘﻘﻨﻴﺔ ﺍﻟﻜﺸﻑ ﻋﻥ ﻭﺠﻭﺩ ﺍﻟﻔﻴﺭﻭﺱ ﻜﻭﺴﻴﻠﺔ ﻟﻠﻜﺸﻑ ﺍﻟﻤﺒﻜﺭ ﻟﻠﺴﺭﻁﺎﻥ
ﻭﻤﻤﺎ ﺴﺒﻕ ﻓﺎﻨﻪ ﻴﺠﺏ ﺍﺠﺭﺍﺀ ﺩﺭﺍﺴﺔ ﻭﺒﺎﺌﻴﺔ ﺸﺎﻤﻠﺔ ﺘﻌﺘﻤﺩ ﻋﻠﻰ ﺩﺭﺍﺴـﺎﺕ ﻤﻴﺩﺍﻨﻴـﺔ 
ﻟﺘﻭﻀﻴﺢ ﺍﻟﺼﻭﺭﺓ ﺍﻟﺩﻗﻴﻘﺔ ﻟﻬﺫﺍ ﺍﻟﻤﺭﺽ ﻭﻟﺘﺤﺩﻴﺩ ﺍﻻﻨﻤﺎﻁ ﺍﻟﻭﺭﺍﺜﻴﺔ ﻟﻬﺫﺍ ﺍﻟﻔﻴﺭﻭﺱ ﻓﻲ ﺍﻨﺤـﺎﺀ  
 ﺍﻟﻤﺴﺘﻘﺎﺓ ﺍﺜﺭ ﻤﻠﻤﻭﺱ ﻓﻲ ﺍﻟﺴﻴﻁﺭﺓ ﻋﻠﻰ ﻫﺫﺍ ﺍﻟﻤﺭﺽ ﺍﻟﺴﻭﺩﺍﻥ ﺍﻟﻤﺨﺘﻠﻔﺔ ﻭﻤﻥ ﺜﻡ ﻴﻜﻭﻥ ﻟﻠﻨﺘﺎﺌﺞ
  .ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ
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CHAPTER ONE 
INTRODUCTION 
Cervical cancer is the growth of abnormal cells on the surface of a 
woman's cervix. Most cervical cancers begin with microscopic changes in 
the cells located in the outer layer of the cervix. These changes, known as 
dysplasia, may develop into cancer. The most common types of cervical 
cancer is squamous cell carcinoma. 
Cervical cancer represents the second most frequent malignant 
tumor of women worldwide with an estimated frequency of 
approximately 440 000 new cases per year, corresponding to about 5.8% 
of the global cancer incidence. 
  Human papillomaviruses (HPVs) are now recognized as the major 
cause of cervical cancer. HPVs are a group of more than 200 viruses. 
They are called papillomaviruses because certain types may cause warts, 
or papillomas, which are benign (non-cancerous) tumors. The HPVs that 
cause the common warts which grow on hands and feet are different from 
those that cause growths in the throat or genital area. Some types of HPV 
are associated with certain types of cancer. These are called “high-risk” 
oncogenic or carcinogenic HPVs. Human papillomaviruses types 16 and 
18  are responsible for about 70%   of cervical cancer (Munoz, 2006). 
 
  More than 50% of vulvar, penile, perianal and anal cancers, in all 
likelihood more  than 20% of oral, laryngeal and nasal cancers contain 
predominantly anogenital high risk HPV types, this leads almost 10% of 
the worldwide cancer burden linked to these infections (zur Hausen, 
1996).  
In 2006, an estimated 10,000 women in the United States were diagnosed 
with this type of cancer and nearly 40% died from it. Cervical cancer 
strikes nearly half a million women each year worldwide (American 
Cancer Society, 2006). Lower rate of cervical cancer in the United States 
is attributable to the success of the widespread use of the Papanicolaou 
(Pap) test, which detects changes in cervical tissue, and is a major tool in 
screening for early identification of cervical cancer. When detected early, 
cervical cancer is highly treatable. 
 
  Africa as a region has one of the highest incidence rates in the 
world and five of the seven countries with the highest rate globally are in 
eastern or southern Africa (Drain, Holmes, Hughes and Koutsky, 2002).  
 
  In the Sudan cervical cancer is the second most common cancer 
observed among woman (Globocan, 2002). The rates of cervical cancer in 
the Sudan was estimated   as <16.8 per 100,000 woman.  
There are no data on the prevalence of human papillomavirus in Sudanese 
women with cervical carcinoma. In the present study the prevalence of 
HPV 16 and 18 was investigated in archival material of cervical 
carcinoma kept at the Department of histopathology, Medical Laboratory, 
University of Gezira. DNA was isolated from formalin fixed, paraffin 
embedded tissue, histologically classified according to the degree of 
differentiated cells to well, moderately and poorly differentiated 
squamous cell carcinoma. 
   
The aim of this cross sectional study is to identify which  HPV 16 and 18 
are  the causative agent for cervical cancer in the Sudan, and to provide 
base line information for eventual preventive measures including vaccine 
trials and other control activities 
 
OBJECTIVES 
 
1. General Objectives: 
 
To detect HPV 16 and 18 in cervical cancer in the Sudan. And to 
determine the frequency  and distribution of HPV 16 and 18 in cervical 
cancer biopsy samples (paraffin embedded tissue blocks) previously 
collected from women in  Central Sudan. 
 
2. Specific Objectives: 
 
To investigate the association of HPV 16 and 18 DNA to various 
grades of cervical carcinoma and their relation or association with age.  
  
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
LITERATURE REVIEW 
 
 
 2. Human Papilloma Virus (HPV): 
 
2. 1. Biological agents and viruses in human cancer: 
 
  Surprisingly, wide spread chronic diseases, previously thought to 
be due to metabolic imbalances or genetic modifications, are increasingly 
linked to infectious events. Approximately 20% of global cancer 
incidence is aetiologically related to specific infections.  About 5% for 
Bacteria (Helicobacter pylori) and helminthes (Schistosoma, 
Opistochoris, and Clonorchis) contribute to the development of gastric, 
bladder and rectal cancers and cholangiocarcinomas (zur Hausen, 2001).                          
Viruses, however, emerge as major causal cancer factors and about 15% 
can be linked to tumor viruses. In addition to hepatocellular carcinoma 
linked to hepatitis B and C virus infections (HBV and HCV); specific 
types of papillomaviruses have been shown to cause a major human 
cancer, cancer of the cervix. They have also been implicated to in a 
number of other anogenital, ororpharyngeal, and cutaneous cancers. 
Epstein-Barr virus (EBV), human herpes virus type 8 (HHV-8), and 
human T-lymphotropic retrovirus type 1 (HTLV-1) represent additional 
identified human tumor viruses (zur Hausen, 2001). 
  There exist good reasons to argue that still other virus types are 
involved in human cancers: Human immunodeficiency viruses type    
HIV-I and HIV-II induce severe immunosuppression and facilitate cancer 
induction by other persisting infections, in particular by HHV-8, Epistein-
Barr virus and human papillomaviruses. Thus these agents contribute 
indirectly to human carcinogenesis. However, specific cutaneous 
papillomavirus infections contribute indirectly to skin carcinogenesis by 
blocking apoptosis in cells exposed to ultraviolet light and permitting the 
survival of UV-damaged cells (Jackson and Storey, 2000). 
 
  It is likely that epidemiological studies may not point to the 
existence of as yet unknown additional tumor viruses if these are 
ubiquitous. Nevertheless, the mere presence of viral DNA within a human 
tumor represent a hint but clearly not proof for an a etiological 
relationship (zur Hausen, 1999). 
2.2 HPV and Cervical Cancer: 
Epidemiologic, cytopathologic, virologic and histologic data have 
established a strong association of HPV infection with carcinoma of the 
cervix (Munoz, Bosch and de Sanjosé, 2003). 
The prevalence of HPV in cervical squamous cell carcinoma 
reported was between 70%-98% ( Farjadian, Asadi, Doroudchi, 
Dehaghani, Tabei, Kumar, and Ghaderi, 2003, Stanczuk, Kay, Allan, 
Chirara, Tswana, Bergstrom, Sibanda, and Williamson, 2003 and Munoz 
et al., 2006). 
Some types of HPV are referred to as “low-risk” viruses because 
they rarely develop into cancer. HPV types that are more likely to lead to 
the development of cancer are referred to as “high-risk.” Both high-risk 
and low-risk types of HPV can cause the growth of abnormal cells, but 
generally only the high-risk types of HPV may lead to cancer. Sexually 
transmitted, high-risk HPVs include types 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 69, and possibly a few others. These high-risk types of 
HPV cause growths that are usually flat and nearly invisible, as compared 
with the warts caused by types HPV–6 and HPV–11. It is important to 
note, however, that the majority of high-risk HPV infections go away on 
their own and do not cause cancer (Walboomers,  Jacobs and Manos, 
1999). 
HPV 16, 18, and a number of additional HPV types have been 
found in about 70% of all biopsies derived from cancer of the cervix 
throughout the world. the remaining 30% being due to other high-risk 
HPV types (such as HPV-31, -33, -35, -39, -45,-51, -66).  (Gissmann and 
Gross 1986)  showed that HPV 16 and 18 are found in a substantial 
number of invasively growing squamous cell carcinomas of the cervix, 
suggesting an etiologic involvement of these viruses in development of 
cervical cancer. 
 
  HPV16 is the most frequently found virus type and accounts for 50 
to 60% of all positive data, the presence of HPV18 vary between 10 and 
20%. HPV45, a type relatively closely related to HPV18, thus cross-
hybridizations between HPV45 and 18 may have led to an overestimation 
of HPV 18 positivity. Many of these types have been found in 
exceptional cases only. The mere presence of HPV DNA in the vast 
majority of biopsies from cancer of the cervix does not prove an 
etiological involvement. Early data pointing to a role derived from 
experimental findings were reviewed by zur Hausen (1996).                         
 
  Although HPV related cancers are more common in women, 
increasing numbers of HPV related carcinomas of anal mucosa are being 
reported among homosexual men. A third group at risk for severe HPV 
infection is neonates. At birth, HPV can infect the mucosa of pharynx and 
cause large wart like lesions that can obstruct the airway (Mahdavi and 
Monk, 2005). 
 
    The evidence linking HPV and carcinoma of cervix has come from 
detection of viral genomes in neoplastic and pre- neoplastic tissues. It is 
now well established that HPV infection is the central causal factor for 
cervical cancer. So the most important risk factor for cervical cancer is 
infection by the human papillomavirus (HPV). Doctors believe that 
women must have been infected by this virus before they will develop 
cervical cancer. 
 
  An Individual is at greater risk of becoming infected with HPV if 
he or she has had multiple sexual partners at any time or is the partner of 
some one who has had multiple sexual partners. Sexual activity at an 
early age also place an individual at increased risk as does a history of 
other sexual diseases in an individual or sexual partners. In addition to 
sexual activity, age is an important determinant of risk of HPV infection 
(Adam, Berkova and Daxnerova, 2000). 
 
  At least 50 percent of sexually active men and women acquire 
genital HPV infection at some point in their lives. By age 50, at least 80 
percent of women will have acquired genital HPV infection (Ho GYF, 
Bierman, Beardsley, Chang and Burk, 1998). 
 Studies suggest that whether a woman develops cervical cancer 
depends on a variety of factors acting together with high-risk HPVs. The 
factors that may increase the risk of cervical cancer in women with HPV 
infection include number of sexual partners, younger age at first 
intercourse, increasing parity, younger age at first full-term pregnancy, 
increasing duration of oral contraceptive use and smoking.  
 
  HPV infections can occur in both male and female genital areas 
that are covered or protected by a latex condom, as well as in areas that 
are not covered. Although the effect of condoms in preventing HPV 
infection is unknown, condom use has been associated with a lower rate 
of cervical cancer (Thomas, Ray, Koetsawang, Kiviat, Kuypers, Qin, 
Ashley and Koetsawang, 2001).  
2.3 The HPV Structure and Genome: 
         Current data support the existence of more than 200 HPV 
genotypes. The entire genomes of about 100 HPV types have been 
isolated and completely sequenced ( Bernard, 2005). These viruses can be 
classified into mucosal and cutaneous HPVs. Within each of these HPV 
groups, individual viruses are designated high risk or low risk according 
to the propensity for malignant progression of the lesions that they cause 
(Munoz et al., 2003). 
           The diameter of papilloma virus (HPV) particles amounts to 
approximaely 55nm. PVs have circular double –stranded DNA genome 
with sizes close to 8kb.The viral DNA is associated with histone-like 
proteins and encapsidated by 72 capsomeres. In spite of their small size , 
their molecular biology is very complex (de Villiers, Fauquet, Broker, 
Bernard and zur Hausen, 2004).  
        The genome of all HPV types consist of closed-circular double –
stranded DNA (Figure.1). It is containing approximately 8 open reading 
frames (ORF) which are transcribed as polycistronic messages from a 
single DNA strand. The structure of the viral genome reveals remarkable 
similarities between different members of this virus group: generally only 
one strand is transcriptionally active, therefore transcription occurs in one 
direction only, and the localization of open reading frames reveals a 
remarkable degree of correspondence (Donos, Katinka and Yaniy, 1982). 
Sequences required for the viral replication and transcription are 
concentrated in a non coding region termed as the upstream regulatory 
region (URR) (zur Hausen, 1996). 
       Papillomaviruses genome can be divided into three regions: a long 
control region (LCR) covering about 10% of the genome, and early (E) 
and a late (L) region. The L genes codes for structural proteins, the E 
region mainly with regulatory functions concerned with persistence, 
DNA replication and activation of the lytic cycle. In short, E1 and E2 are 
the two viral proteins that are required for viral DNA replication, together 
with the host cell DNA replication machinery, E4 and E5 proteins are 
needed for amplification of the viral genome in the upper layers of the 
epithelium. The E6 and E7 proteins of high-risk HPV types are 
oncogenic. They cooperate to immortalize cells and also induce genomic 
instability. E6 and E7 abrogate the activity of the cellular tumor 
suppressor proteins p53 and Rb, respectively. E6 also increases 
telomerase activity (Huibregtse and Beaudenon, 1996). 
         Gissmann and Schwarz (1986) noticed that papillomaviruses 
expressed parts of the early region (E) of their genome in cell lines of  
genital cancer. They concluded that  HPV might be  involved in inducing 
and/or maintaining the transformed phenotype of cancer cells. 
          Infection with high-risk HPV types interferes with the function of 
cell proteins and also with the expression of cellular gene products. 
Microarray (gene chip) analysis of cells infected with HPV-31 has shown 
that 178 genes are up regulated and 150 genes are down regulated by 
HPV (Chang and Laimins, 2000). 
 
2.4 HPV Oncogenes and their interaction 
  
2.4.1   E6 Oncoprotein 
 
The E6 oncoprotein of high-risk human papillomavirus type 16 
(HPV16) plays a role in the cellular transformation process. HPV16 E6 
oncoproteins enter the nucleus of host cells via multiple pathways (Le 
Roux and Moroianu, 2003). Efficient immortalization of keratinocytes 
requires the combination of E6 and E7 (Munger, Phelps, Bubb, Howley 
and Schlegel, 1989a).  
 E6 proteins exert their functions by interacting with cellular 
proteins. High-risk HPV encoded E6 protein that forms a complex with 
p53 leading to functional inactivation (Werness, Levine and Howley, 
1990). High-risk HPV E6 proteins have anti-apoptotic activities and can 
interfere with the anti proliferative functions of p53.  HPV depends on the 
cellular DNA synthesis machinery and must stimulate S-phase 
progression to replicate their genome, resulted in P53 over expression 
which represents a major impairment for viral replication. 
 
High-risk HPV expressing cells have lower p53 levels compared 
with normal uninfected primary cells (Hubbert, Sedman and Schiller, 
1992). High-risk HPV E6 proteins induce rapid degradation of p53 
through ubiquitin-dependent proteolysis (Scheffner, Werness, Huibregtse, 
Levine and Howley, 1990). This results in bypassing the normal growth 
arrest signals at the G1/S and G2/M checkpoints leading to accumulation 
of mutations and later transformation (Fehrmann and Laimins, 2003).  E6 
proteins of low-risk HPVs did not affect p53 stability or inactivate it 
(Scheffner et al., 1990).  
  
Independent of p53  HPV16 E6 was reported to activate telomerase 
through up-regulation of hTERT, the catalytic subunit of telomerase, 
which is a critical step in cellular transformation (Klingelhutz, Foster and  
McDougall, 1996). Activation of telomerase is closely associated with 
progression of CIN and cervical carcinoma, and telomerase might be a 
useful marker for cervical carcinoma (Leng, Bian, Sun, Fan and Chen,   
2002). 
 
2.4.2   E7 Oncoprotein: 
 
HPV E7 protein binding and degradation of the retinoblastoma 
protein (Rb) are necessary for its transforming activity. High-risk HPV 
E7 proteins interact with pRb and induce its proteolytic degradation. 
The E7 protein  together with E6 provide the major transforming 
activities of HPVs. Expression of the E7 protein in the absence of other 
viral gene products leads to the transformation of rodent fibroblasts. 
While E7 alone can immortalize human keratinocytes, the presence of E6 
greatly enhances the frequency at which this can occur (Hubbert, Demers 
and Galloway, 1999). 
 
HPV-16 E7 forms complexes with hypophosphorylated Rb, 
leading to its inactivation and permits S phase entry (Cobrinik, Dowdy, 
Hinds, Mittnacht and Weinberg, 1992). HPV E7 abrogates Rb mediated 
regulation of the S transition of the cell division cycle. Rb binds E2F-1 
and actively represses transcription from promoters containing E2F-1 
sites. Upon phosphorylation late in G1, the hyperphosphorylated Rb does 
no longer interact with E2F-1, converting E2F-1 into a transcriptional 
activator.  High-risk HPV E7 proteins can interact with Rb and induce its 
proteolytic degradation, decreasing the abundance of growth suppressive 
hypophosphorylated pRb increasing the pool of transcriptionally active 
E2F-1 (zur Hausen, 1996). 
  
Destabilization of the Rb tumor suppressor and stabilization of p53 
contribute to HPV16 E7 induced apoptosis and the ability of E7 to induce 
cellular transformation (Gonzalez, Stremlau, He, Basile and Munger, 
2001). Binding of E7 to hypophosphorylated Rb prevents it from binding 
to E2F-1 and thereby promoting cell cycle progression allowing for 
productive replication of HPV genes.  
 HPV-16 E7 plays a major role in inducing centrosome related 
mitotic disturbances.  Abnormal centrosome duplication induced by HPV 
E7 rapidly results in genomic instability and aneuploidy, one of the 
hallmarks of a cancer cell (Duensing, Crum, Munger and Duensing, 
2001a). This activity is, therefore, likely to be functionally relevant to the 
contribution of high-risk HPVs to malignant progression.  E7 of HPV 38 
was shown to have in vitro transforming activities (Calderia, Filotico, 
Accardi, Zehbe, Franceschi.and Tommasino, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
  
 
  
 
  
 
 
 
 
 
Figure 1: HPV 16 genome  
2.5 HPV Life Cycle and Transmission:  
  
       Human papilloma viruses (HPVs) induce hyper prolifarative lesions 
of cutaneous and mucosal epithelium (Fehrmann and Laimins , 2003). 
The productive life cycle of HPV is directly linked to the epithelial cell 
differentiation. Infection by papilloma viruses is believed to occur 
through micro traumas in the epithelium, exposing the basal cells to enter 
by viruses (Howley and Lowy, 2001). Following entry into keratinocytes 
in the basal layer, HPV replicates as the basal cells differentiate and 
progress to the surface of the epithelium. In the basal layers, viral 
replication is considered to be non productive and the virus establishes 
itself as a low-copy-number episome by using the host DNA replication 
machinery to synthesize its DNA on average once per cell cycle (Flores, 
1997). In the differentiated keratinocytes of the suprabasal layers of the 
epithelium, the virus switches to a rolling-cycle mode of DNA 
replication, amplifies its DNA to high copy number, synthesizes capsid 
proteins and causes viral assembly to occur (Flores, 1999). Since HPVs 
encode only 8 to 10 proteins, they must utilize host cell factors to regulate 
viral transcription and replication. 
      
In low grade cervical lesions, the HPV genomes are found exclusively as 
episomal DNA molecules. In contrast, in cervical carcinomas, high-risk 
HPV genomes are integrated into the cellular host DNA (Storey, 
Greenfield, Banks, Pim, Crook, Crawford and Stanley, 1992). Durst et al 
(1987) detected  the integration of   papillomavirus sequences  near 
cellular oncogenes in some cervical carcinomas. 
 
        Integration of HPV DNA has been suggested to be an important 
event in the development of cervical cancer, since this often results in a 
disruption of the E2 ORF. Integration thus abrogates the inhibitory action 
of the E2 protein on the viral promoter of the E6 and E7 genes. This 
results in high level expression of E6 and E7 and most likely contributes 
to cellular transformation that eventually results in cancer (Longworth 
and Laimins, 2004). 
 
The E6 and E7 genes encode viral oncoproteins that target p53and 
Rb respectively during the viral life cycle; these proteins facilitate stable 
maintenance of episomes and stimulate differentiated cells to reenter the 
S phase. The E1and E2 proteins act as origin recognition factors as well 
as regulators of early viral transcription. The functions of the E5 and E1-
E4 proteins are still unknown but these proteins have been implicated in 
modulating late viral functions. The L1and L2 proteins form icosahedral 
capsids for progeny virion generation. The characterization of the cellular 
targets of these viral proteins and the mechanisms regulating the 
differentiation-dependent viral life cycle remain active areas for study of 
these important human pathogens (Longworth and Laimins, 2004). 
Papillomavirus is highly persistent in the environment, on contaminated 
objects, linen, floors. Skin infections can occur through indirect or direct 
contact. Transmission of human papillomaviruses is facilitated by the 
presence of abraded or macerated epithelial surfaces. Anogenital 
infections are mainly transmitted by sexual contact. HPV DNA is rarely 
detected in sexually inexperienced young women. There exists a 
correlation between the number of sexual partners and the prevalence of 
HPV infection reviewed in zur Hausen (1996).                                          
Of the more than 100 types of HPV, over 30 types can be passed 
from one person to another through sexual contact. Most HPV infections 
occur without any symptoms and go away without any treatment over the 
course of a few years. However, HPV infection sometimes persists for 
many years, with or without causing cell abnormalities.  
2.6 Immune Response to HPV: 
HPV infections are largely shielded from the host immune 
response because they are restricted to the epithelium (Stanley, 2006). 
Humoral and cellular immune responses have been documented, but 
correlates of immunity have not been established. Serum antibodies 
against many different viral products have been demonstrated. The best 
characterized and most type-specific antibodies are those directed against 
conformational epitopes of the L1 capsid protein assembled as virus-like 
particles (VLPs). Not all infected persons have antibodies; in one study, 
54%-69% of women with incident HPV 16 or 18 infections had 
antibodies (Carter, Koutsky and Hughes, 2000). Among newly infected 
women, the median time to seroconversion is approximately 8 months 
(Ho, Studentsov and Bierman, 2004). 
 
 The nature of the interaction between papillomaviruses (PV) and 
their infected host has led to the identification of ways in which the viral 
oncoproteins can transform the infected host cells into cancer cells. As 
viral persistence is required for malignancy, and persistence requires 
avoidance of immune attack by the host, defining the relationship 
between PV and the immune system is also paramount in understanding 
tumorgenesis. 
 
It has emerged that PV have evolved several ways in which to 
prevent clearance by the host immune system. The limitation of the PV 
replication cycle to the epithelium, together with low level expression of 
the virus proteins and absence of inflammation, minimizes the exposure 
of virus to immune cells. In addition, more recently it has been shown 
that, like many other viruses, PV can directly subvert the immune 
response, including interference with the interferon pathway, modulation 
of antigen presentation, inhibition of interleukin-18 activity and down-
regulation of major histocompatibility class1 on infected cells. 
Collectively these mechanisms explain how PV lesions are able to persist 
for long periods of time in immunocompetent host (Obrien and Campo, 
2002). 
 
2.7 Diagnosis and screening: 
 
The most widely used screening approach to detect squamous 
intraepithelial lesions is conventional cervical cytology, followed by 
investigation of positive women with colposcopy and directed biopsy. 
Although cytology-based screening programs in Europe and North 
America have been followed by a substantial reduction in mortality from 
cervical cancer (Anhang, Annekathryn, Sue and Goldie, 2004), a wide 
range of rates has been reported for the sensitivity and specificity of 
cytology in different settings. Saslow, Runowicz, Solomon, Moscicki, 
Smith, Eyre and Cohen  (2002) revealed that the relative insensitivity of 
conventional cytology triggers the need of other screening tools for 
optimal early detection of cervical cancer.  
 
The knowledge gained during the last 20 years on necessity of 
persistent high–risk HPV infection to progress to cervical cancer has 
provided the basis for evaluation of clinical utility of testing for cervical 
cancer associated HPV types (Nobbenhuis, Walboomers, Hemerhorst and 
Rozendaal, 1999). 
 
 
2.8 HPV DNA detection assay: 
Members of the HPV family do not lend themselves to culture 
invitro: hence, detection of HPV relies strictly on molecular analysis of 
HPV DNA sequence (Allied for cervical cancer prevention, 2004) 
The US Food and Drug Administration (FDA) has approved an 
HPV test and allowed it to be used in conjunction with the pap smear test 
to screen for HPV infection in women age 30 years (Masumoto, Fujii, 
Mitsuya, Ishikawa, Makio Mukai, Akiko Ono, TakashiIwata, Kaneyuki, 
and ShiroNozawa, 2004). 
Most exposure measurement for HPV is based on detection of the 
viral DNA from biopsy tissues or exfoliated cells collected from the 
presumptive site of infection. Positive DNA tests are markers of prevalent 
infection. The absence of viral DNA is usually interpreted as absence of 
HPV infection, although undetectable latent infection cannot be ruled out. 
HPV DNA can be detected in the blood of women with more 
advanced cervical carcinomas but not in the blood of women with pre-
cursor cervical lesions. So the role of HPV DNA in the circulatory system 
appears not be of diagnostic significance and HPV DNA is only 
detectable in women with more advanced cervical cancers (Kay, Allan 
and Denny, 2005). 
  Several molecular techniques have been used to detect HPV in 
cervical samples, including Hybrid Capture II (HCII) assay and the 
Polymerase Chain Reaction (PCR). The most common primers used in 
PCR to detect genital HPV are PGMY09/11 and GP5+/6+ (De Roda 
Husman, Walboomers, Van Den Brule (1995) and Strauss, Jordens, 
Desselberger (2000). Fuessel Haws, He and Rady (2004) found that 
PGMY/GP+ nested PCR detected more HPV types than did MY/GP+ 
nested PCR. The determination of the HPV types may be done by several 
methods including Type-Specific PCR (TS-PCR) and Restriction 
Fragment Length Polymorphisms (RFLP). The latter relies on distinct 
patterns of amplicon digestion with seven restriction enzymes. However, 
these patterns may be difficult to discriminate, especially when clinical 
specimens contain two or more HPV types. 
  Alternatively, PCR with type-specific primers targeting E6 and/or 
E7 non-conserved regions is a highly sensitive method that is easy to 
interpret and allows characterization of infections by multiple types 
(Lungu1, Wright and Silverstein, 1992 Kado, Kawamata and Shino, 
2001). 
 
2.9 Treatment of cervical cancer 
 
The best results of treating of cervical cancer are obtained in 
oncological units staffed by pelvic surgeons and radiological oncologists. 
Micro-invasive (stage 1a) cancer is treated by simple total hysterectomy. 
Stage 1b cancer may be treated either by radical hysterectomy or by 
radiotherapy. Both give similar 5-years survival rates. More advanced 
cervical carcinoma is treated by radiotherapy, although in some centres 
chemotherapy is being tried. 
 
2.10 Prevention and vaccination: 
The discovery of HPV as a cause necessary of cervical cancer has 
opened new preventive strategies for the control of cervical cancer both 
in primary prevention (via the introduction of prophylactic HPV 
vaccines) and on secondary prevention (via the introduction of screening 
for HPV). The rationale for the introduction of HPV vaccination and 
HPV typing in the control of cervical cancer is based on the following 
facts: -Genital HPV infection is one of the most common sexually 
transmitted diseases.  
Although most HPV infections are transient, persistent infections 
with a subset of 15 HPV high-risk types are now considered as a 
necessary cause of cervical cancer (Walboomers et al 1999) and also are 
known to contribute to the development of other genital cancers and 
cancer of the oropharynx as well as being the cause of genital warts. HPV 
16 and 18 are the most common types, responsible for about 70% of 
cervical cancers and HPVs 6 and 11 are the main cause of genital warts. 
The current preventive strategies based on cytologic screening have been 
shown to have limitations, as they have been found to be insensitive for 
the detection of cancer and precancer, and requiring many rounds of 
screening to achieve programmatic effectiveness. Three types of HPV 
vaccines are under development: Prophylactic vaccines aimed to prevent 
HPV infections and associated diseases. Therapeutic vaccines aimed to 
induce regression of HPV induced lesions and Chimeric (combined 
prophylactic and therapeutic) vaccines with both properties. Candidate 
prophylactic vaccines currently under evaluation are based on 
papillomavirus L1 virus-like particles (VLPs). 
 
 One of the vaccines currently under evaluation is quadrivalent and 
contains L1 VLPs of HPV 6, 11, 16 and 18. The other vaccine is bivalent 
and contains L1 VLPs of HPV 16 and 18. Results of ongoing trials in 
human volunteers have shown that these two vaccines are well tolerated 
,induce high serum antibody titers and show over 95% efficacy in 
preventing infection and their associated precancerous lesions ( Villa, 
Costa, Petta, Andrade, Ault, Giuliano, Wheeler, Koutsky, Malm, 
Lehtinen, Skjeldestad, Olsson, and Steinwall, 2005 and Harperet, Franco, 
Wheeler, Ferris, Jenkins, Schuind, Zahaf, Innis, Naud, De Carvalho, 
Roteli-Martins, Teixeira and Blatter, 2004). 
Researchers at the National Cancer Institute (NCI) and elsewhere are 
studying how HPVs cause precancerous changes in normal cells and how 
these changes can be prevented. For example, HPV E6 interferes with the 
human protein p53. This protein is present in all people and acts to keep 
tumors from growing (Howley, Ganem and Kieff, 2004). This research is 
being used to develop ways to interrupt the process by which HPV 
infection can lead to the growth of abnormal cells. 
In June 2006, a new vaccine produced by Merck called Gardasil 
that protects against certain strains of HPV was approved by the U.S. 
Food and Drug Administration (FDA). Gardasil prevents infection of four 
strains of HPV—two strains (16, 18) that cause 70% of cervical cancer 
cases and two strains (6, 11) that cause 90% of genital warts cases. It does 
not protect against all types of cervical cancer-causing HPV. Therefore, 
regular Pap tests remain a critical tool for early detection of precancerous 
cells (Garland, 2006). Gardasil should be administered in three doses over 
six months. Presently, there is only enough research to show vaccine 
effectiveness for 5 years. Further research will determine whether booster 
shots are needed. 
Also, scientists are developing HPV vaccines that will be stable at 
room temperature. The goal is to develop a vaccine that does not require 
refrigeration for storage and distribution, which could allow for its use in 
many climates and locations. 
Researchers at the NCI and elsewhere are also studying what 
people know and understand about HPV and cervical cancer, the best way 
to communicate to the public about the latest research results, and how 
doctors are talking with their patients about HPV. This research will help 
to ensure that the public receives accurate information about HPV that is 
easily understood, and will facilitate access to appropriate tests for those 
who need them. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
MATERIAL AND METHODS  
 
1. Study area:  
  
This study was conducted at the Department of Molecular Biology, 
Institute of Nuclear Medicine and Oncology (INMO), University of 
Gezira. Sections of paraffin embedded tissue of cervical cancer 
histopathologically confirmed were selected from Department of 
Histopathology, medical laboratory of University of Gezira, during the 
period from January 2006 to June 2007. 
 
2. Study design:  
   
It is a retrospective cross sectional laboratory-based study on 
histopathologically confirmed cervical cancer.  
 
3. Selection criteria: 
 
? Paraffin embedded tissue blocks during1/1/2006-30/6/2007. 
? -Undamaged/undistorted tissue blocks (visual evaluation) 
? -Histology result showing the presence of cervical cancer. 
 
4.  Study population: 
All study subjects were women whose age ranged between 30 to70 
years. According to the age of the study subjects, the population was 
divided into two groups ≥ 45 and   ≤ 44 years.  
Figure.1 shows the distribution of subjects who participated in this 
study: 30% were females their age was ≥ 44 year (12 individuals) while 
70% were females whose age was ≤ 45 old (28 individuals). 
A number of 21 women (52.5 %) were from rural areas (villages in the 
Gezira state) and 19 women (47.5%) were from urban areas (towns in the 
Gezira state) (Table.1). 
 
5. Degree of differentiated cells: 
 
According to degree of cancer, study samples were divided into three 
types, well differentiated cells, moderately differentiated cells and poorly 
differentiated cells. Table 2 shows that Cells from 21 women (52.5%) 
were well, from 9 women (22.5%) were moderately and from 10 women 
(25%) were poorly differentiated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Age distribution of patients with cervical cancer 
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               Table 1: Distribution of the study subjects according to the               
location. 
  
 
 Frequency % 
Rural area 21 52.5% 
Urban area 19 47.5% 
Total 40 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
Table2: Distribution of samples according to degree of cancer. 
  
 
 Frequency % 
well differentiated cells 21 52.5 % 
Moderately differentiated 9 22.5 % 
poorly differentiated 10 25 % 
Total 40 100 % 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
6. Sample size 
  
All cervical samples (n= 40) included in this study (embedded in 
paraffin wax) were previously diagnosed as squamous cell carcinoma 
during 1/1/2006 to 30/6/2007. 
 
7. Study variables:  
 7.1 Dependent variables  
   
? Presence of HPV  
? Presence of different HPV genotypes (16/18) 
 
 7.2 Independent variables 
 
? Age  
? Geographical location 
? Degree of cell differentiation  
 
8. Methods of data collection  
 
Demographic and clinical data were collected according to a 
certain questionnaire (including sample data, personal data and types of 
differentiated cells) and were obtained from records of the 
Histopathology Department of the Medical Laboratory University of 
Gezira. 
9. Laboratory methods  
 
9.1. Tissue sections preparation for polymerase chain 
reaction (PCR):  
  
From each cervical cancer patient's paraffin block, small sections 
of 30-50 microns were collected into a screw capped Eppendorf tube. To 
avoid cross contamination, each block was cut with new gloves and new 
disposable microtome blade. 
 
9.2 De-paraffinization and re-hydration of sections:   
 
          One ml of xylene was added two times to a screw capped 
Eppendorf tube containing sections of cervical cancer embedded in 
paraffin. Then sections were incubated at 37°C for 30 min, vortexed and 
centrifuged at 800g per 5 min. The pellet was re-hydrated with serial 
dilutions   of absolute ethanol, 75% ethanol, 50% ethanol, 25% ethanol 
and sterile water, vortexed and centrifuged for 3 min at maximum speed 
after each washing and the supernatant was discarded.  
 
9.3 DNA Extraction:  
 
DNA was extracted according to the steps described in DNA 
extraction kit purchased from Sacace biotechnologies-Casera –Italy. The 
pellet obtained from previous steps was treated with 1500 µl of  Reagent 2 
(lysis buffer ), vortexed, incubated at -20°C for 5 min and centrifuged at 
3000g for 15 min. The supernatant was discarded. 150 µl of Reagent 3, 25 
µl of Reagent 4 (proteinase K) and 10 µl of Reagent 5 were added to the 
pellet and incubated at 50°C overnight. 90 µl of Reagent 6 were added to 
each tube, vorexed vigorously and centrifuged at 800g for 15 min. The 
supernatant was transferred to a new sterile 1.5 ml Eppendorf tube. 750 µl 
of absolute  ethanol were added to each tube and mixed by inverting. 
Then  centrifuged at 7000g for 5min and the supernatant was discarded. 
This step was repeated by using 1ml 70%cold ethanol and tubes were 
incubated with open caps for 10 min. The pellet (containing the DNA) 
was re-suspended in 50 µl of Reagent 7 (DNA eluent ), shaked for 2 hours 
using a shaker and stored at -20°C until used. 
9.5 Polymerase chain reaction (PCR): 
 
9 .5.1. Amplification of HPV:  
 
Type specific primers (primer for HPV 16 and HPV18) were used 
to detect HPV16 and 18 DNA in cervical cancer. Amplification was 
performed according to HPV16/18 kit from Sacace technologies- Casera 
–Italy. The final reaction volume of 40 µl containing 20 µl mix-1 
(contained in PCR tubes), 10 µl of mix-2 and 10 µl of extracted DNA 
(sample). Negative control, positive HPV16 DNA and positive control 18 
DNA tubes contained 10 µl  of DNA buffer, 10 µl  of HPV 16 DNA 
and10 µl  of HPV18 DNA respectively. Samples and controls were 
amplified  using Gene Amp PCR system 9700. The PCR programme was 
described in Table.3. 
 
 
Table: 3 PCR Programme used for amplification of HPV genes:  
 
Cycles time Temperature steps 
Pause 95°C 0 
1 5min 95°C 1 
15sec 95°C 
25sec 65°C 
  
45 
25sec 72°C 
  
2 
1 1min 72°C 3 
storage 4°C 4 
 
 
 
 
9.5.2. Gel-electrophoresis:  
 
The PCR products were visualized in 2%Agarose gel with 0.5 
µg/ml Ethidium bromide. Ten micro liters of 100bp DNA ladder and PCR 
product was loaded on the gel. Gel-electrophoresis was performed at 
120Vand 36mA for about 60 minutes, Pictures were taken using Gel 
documentation system (Gel mega, digital camera and software in a 
computer). 
9.5.3. Interpretation of PCR results: 
According to manufacture HPV16/18 kit (from Sacace 
technologies- Casera –Italy) manual, the PCR product length for HPV16 
should be 325bp and 425bp for HPV18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
CHAPTER FOUR 
RESULTS 
 
Data presented in this study were obtained from questionnaire and 
laboratory investigation. All study subjects were women cases.  
Histopathological diagnosis was confirmed to be as squamous cell 
carcinoma.  
 
1. Results according to Type Specific Polymerase Chain 
Reaction (TS PCR): 
 
? Using PCR human papilloma viruses (HPV 16 and 18) were 
detected in 14 (35%) of the study specimens while they were not 
detected in 26 specimens (65%) (Figure 1). 
? The PCR product size was 325 bp and 425 bp for HPV16 and 
HPV18, respectively. Figure 2 shows picture of PCR result. 
? The HP virus was detected in 10 individuals with ages ≥45 and in 4 
individuals with ages ≤ 44 (Table 1). 
? The HP virus was detected in 8 individuals from rural areas and in 
6 individuals from urban areas (Table 4).  
? HPV16 and HPV18 were detected as a single infection in 8 
samples (57.1%) and 4 samples (28.6%) respectively. HPV16+18 
as mixed infections was detected in 2 (14.3) of positive samples 
(Figure 3 and Table 2).  
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Figure 1: The positivity of HPV 16 and 18among patients with cervical     
 cancer.  
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Figure 2:Ethidium bromide stained agarose gel  2% electrophoresis 
of HPV PCR products, carried out on DNA samples  
extracted from paraffin embedded tissue blocks, Lane 
M:100bp ladder, (Arrows shows 300 and 400 band), Lane N 
negative control, Lane C1 positive control for HPV16, Lane 
C2 positive control for HPV18,Lane 1-2-3-4-5-6-7-8 
extracted DNA samples. 
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Figure 3: The frequency of HPV16 and 18 (as a single and mixed 
infection) in cervical cancer patients in the positive samples to 
PCR test. 
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Figure 4: The relation between HPV types and the degree of cell   
differentiation. 
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 2. Degrees of differentiated cells and types of the virus: 
 
In this study within the 8 samples which contained HPV16 DNA: 
one was moderately differentiated cells and 7 were well differentiated 
cells. Out of 4 samples tested positive for HPV18 DNA 2 were from 
moderately differentiated cells and 2 were from well differentiated cells. 
The 2 samples which tested positive for HPV 16 and 18 DNA were from 
well differentiated cells. Non of the samples that contained HPV were 
from poorly differentiated cells (Figure 4). 
 
3. The relation between the location of the study subject and the PCR 
results: 
Table 4 shows that 8 out of 14 (total of positive samples) of study 
subjects were from rural areas and 6 out of 14 were from urban areas.   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Age  ≤ 44 ≥ 45 Total 
PCR + ve 4 10 14 Result PCR - ve 8 18 26 
Total 12 (30%) 28 (70%) 40  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: The results of HPV type specific (16 and18) PCR and 
the age of cervical cancer patients  
  
 
 
 
  
  
HPV Type detected 
 
HPV 16 HPV 18 HPV 16+18 
Total 
PCR +ve 8 4 2 14 
Result 
PCR - ve - - - 26 
Total  8 4 2 40 
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
Table 2: The relation between type of HPV and PCR used to detect HPV 16 
and 18 in cervical cancer patients  
Table 3: The relation between the type of HPV and the degree of 
differentiated cells in cervical cancer patients  
 
  
Degree  of cell Differentiation  Poor Mod Well Total 
16 - 1 7 8 
18 - 2 2 4 
16+18 - - 2 2 
Type of 
virus 
-ve 10 6 10 26 
Total 10 9 21 40 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Table 4: HPV positivity among patients with cervical cancer from 
rural and urban areas  
 
  
 
Result  + ve - ve Total 
Rural area 8 13 21 Location Urban area 6 13 19 
Total 14 26 40  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
CHAPTER FIVE 
 
DISCUSSION 
 
  
The number of women contracting cervical cancer every year was 
estimated to be 500,000 patients. The association between HPV and 
cervical cancer has now been assessed in various case-control and cohort 
studies. 
 
High risk HPV 16 and 18 were proved to be the etiological agents 
for cervical cancer by many scientists (Gissmann and Gross 1985, zur 
Hausen, 1996 and Clifford et al 2003). This study aimed to detect and 
identify HPV 16 and 18 that may be present in sections of paraffin 
embedded tissue of cervical cancer. 
 
                The overall positivity for HPV in this research was 35% (14/40), 
however, the posativity for HPV that was reported before by many 
authors was 87% (Clifford et al., 2003), 97% (Stanczuk et al., 2003) and 
94% (Ebatia, 2005).The low positivity in this study may be due to the fact 
that different PCR primers and diverse molecular techniques were used 
and their sensitivity and specificity are different. Some of the authors 
used HPV general primers and applied low annealing temperature to 
increase the sensitivity but decrease the specificity. This may lead to false 
positive results due to non specific amplification. Some of those authors 
combined two techniques PCR and Hybridization to enhance their 
sensitivity and specificity. The storage condition of PCR reagents may 
decrease their efficiency and sensitivity. Also this low rate of cervical 
cancer in the Sudan is possibly due to the conservative society in the 
Sudan that mean there are relatively no multiple sexual partners which is 
an important factor that places an individual at increased risk as it was 
reviewed by Adam et al (2000). Additionally, cervical cancer in the 
Sudan may be caused by other variant of HPV 16 and 18 and could not be 
detected by the used primers.  
 
The results of the present study concerned with HPV 16 and 18 
frequencies, HPV 16 was identified in 57% of the positives was 
comparable or in agreement with those reported before. Clifford et al 
(2003) detected HPV16 in 46-63%, Zur Housen,1987 in 50% and 
Stanczuk et al (2003) in 6% of the cervix squamous cell carcinomas.  
 
In this study, HPV 18 was identified in 29% of the positives, which 
is more than that reported by Clifford et al (2003) (10-14%) and Zur 
Housen, 1987 (20%). However, HPV18 was not detected in a study in 
Iran (Farjadian et al., 2003). Accordingly, HPV16 is the most common 
HPV type associated with cervical carcinoma in Central Sudan. The 
predominance of HPV 16 over the other genotypes in this study fits well 
with previous reports from different geographical areas; prevalence of 
HPV 16 was 78.3 % in Poland and 76.5 % in Germany (Bosch et al., 
2002). 
 
An interesting finding in this study was the relatively higher rate of 
HPV infection in the early stage of cancer (well differentiated squamous 
cell carcinoma). This finding reveals the importance of the use of HPV 
detection as screening tool for early detection of cervical cancer.   
 
HPV 16 and 18 were detected more in women aged ≥ 45 than in 
women aged ≤ 44, This result shows that  women ≤ 44 years have low 
rates and this supported the previous explanation for the lower prevalence 
of HPV 16 and 18 as due to the conservative nature of  the Sudanese  
society. Also this result agrees with Ho GYF et al (1998) who reported 
that, at least 50 % of sexually active men and women acquire genital 
HPV infection at some point in their lives. By age 50, at least 80 % of 
women will have acquired genital HPV infection. Cervical cancer is more 
common in older women (≥ 45 years), suggesting infection at a younger 
age and slow progressing to cancer. 
 
In this study we found that no significant differences of HPV 
infection among rural and urban areas were observed (p ≥ 0.05). This 
may be due to the fact that there is no primary health care programmes    
targeting specific areas in the Sudan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
  
Cervical cancer, which continues to plague woman all over the 
world, remains a major focus of cancer research. And the role of HPV 16 
and 18 in association with other factors has been extensively studied in 
relation to cervical cancer. Since the available therapeutic modalities are 
still not 100% effective in curing this disease, the prevention is still 
advocated by gynecological oncologists. 
          
In the present study we found that there is a strong association 
between HPV16 and 18 infections and cervical cancer in Sudanese 
women. Also this result revealed that HPV16 was the prevailing HPV 
genotype identified in samples collected from women with cervical 
cancer in Central Sudan. 
Also we found that women ≥ 45 have high rate of HPV cervical 
cancer. 
 
 
 
 
 
 
 
 
 
 
 
                           
RECOMMONDATIONS 
 
1. Further study with large sample size and involving all part of 
the Sudan is recommended to get conclusive results on the 
situation of HR-HPV infection. 
 
2. We recommend the establishment of a national cervical 
cancer registry system. This is of paramount importance for the 
control and prevention of cervical cancer. 
3. We recommend a study to determine the economical 
importance of HR-HPV infection in the Sudan and to determine 
the feasibility to introduce a vaccine.  
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